Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

D. Hellmann, Matthew; Ciuleanu, Tudor–Eliade; Płużański, Adam; Seok Lee, Jong; A. Otterson, Gregory; Audigier-Valette, Clarisse; Minenza, Elisa; Linardou, Helena; A. Burgers, Sjaak; Salman, Pamela; Borghaei, Hossein; S. Ramalingam, Suresh; R. Brahmer, Julie; Reck, Martin; J. O’Byrne, Kenneth; J. Geese, William; Green, George; Han, Chang; D. Szustakowski, Joseph; Bhagavatheeswaran, Prabhu; Healey, Diane; Fu, Yali; E. Nathan, Faith; Paz‐Ares, Luis

doi:10.1056/nejmoa1801946

Public

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Published in New England Journal of Medicine • Apr 16, 2018

Authors:

Matthew D. Hellmann

Tudor–Eliade Ciuleanu

Adam Płużański

Abstract

BACKGROUND: Nivolumab plus ipilimumab showed promising efficacy for the treatment of non-small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a potential biomarker of benefit. In this part of an open-label, multipart, phase 3 trial, we examined progression-fr...

Subject

Nivolumab

Ipilimumab

Lung cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!